The downregulation of HDC expression led to the activation of the IL-6/STAT3/S100A9 pathway, stimulating Th17 cells to secrete IL-17A, thereby promoting ovarian cancer progression, which suggests that HDC may be a potential therapeutic target for the comorbidity of ovarian cancer and depression. Here, STAT3 is linked to ovarian carcinoma.